Anti-(candida Heat-shock Protein Hsp 90) (human Monoclonal Hsp90mab Fragment)
Anti-(candida Heat-shock Protein Hsp 90) (human Monoclonal Hsp90mab Fragment) Uses, Dosage, Side Effects, Food Interaction and all others data.
Anti-(candida Heat-shock Protein Hsp 90) (human Monoclonal Hsp90mab Fragment) is under investigation in clinical trial NCT00217815 (Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer).
| Trade Name | Anti-(candida Heat-shock Protein Hsp 90) (human Monoclonal Hsp90mab Fragment) |
| Generic | Efungumab |
| Efungumab Other Names | Efungumab, Hsp-90mab, Hsp90mab, Immunoglobulin, anti-(candida heat-shock protein hsp 90) (human monoclonal hsp90mab fragment), Mycograb |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Anti-(candida Heat-shock Protein Hsp 90) (human Monoclonal Hsp90mab Fragment)
